You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameOlaparib
Accession NumberDB09074
TypeSmall Molecule
GroupsApproved
DescriptionLynparza is an inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, including PARP1, PARP2, and PARP3. PARP enzymes are involved in normal cellular homeostasis, such as DNA transcription, cell cycle regulation, and DNA repair. Olaparib has been shown to inhibit growth of select tumor cell lines in vitro and decrease tumor growth in mouse xenograft models of human cancer both as monotherapy or following platinum-based chemotherapy. Increased cytotoxicity and anti-tumor activity following treatment with olaparib were noted in cell lines and mouse tumor models with deficiencies in BRCA. In vitro studies have shown that olaparib-induced cytotoxicity may involve inhibition of PARP enzymatic activity and increased formation of PARP-DNA complex, resulting in disruption of cellular homeostasis and cell death.
Structure
Thumb
Synonyms
4-(3-{[4-(cyclopropylcarbonyl)piperazin-1-yl]carbonyl}-4-fluorobenzyl)phthalazin-1(2H)-one
External Identifiers
  • AZD 2281
  • AZD-2281
  • AZD2281
  • KU59436
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
LynparzaCapsule50 mgOralAstrazeneca Canada Inc2016-05-16Not applicableCanada
LynparzaCapsule50 mg/1OralAstra Zeneca Pharmaceuticals Lp2014-12-23Not applicableUs
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNIIWOH1JD9AR8
CAS number763113-22-0
WeightAverage:
Monoisotopic:
Chemical FormulaNot Available
InChI KeyNot Available
InChI
IUPAC Name
4-{[3-(4-cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorophenyl]methyl}phthalazin-1-ol
SMILES
Pharmacology
IndicationOlaparib is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated as monotherapy in patients with deleterious or suspected deleterious germline BRCA mutated (as detected by an FDA-approved test) advanced ovarian cancer who have been treated with three or more prior lines of chemotherapy.
Structured Indications
PharmacodynamicsNot Available
Mechanism of actionOlaparib is an inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, including PARP1, PARP2, and PARP3. PARP enzymes are involved in normal cellular homeostasis, such as DNA transcription, cell cycle regulation, and DNA repair. Olaparib has been shown to inhibit growth of select tumor cell lines in vitro and decrease tumor growth in mouse xenograft models of human cancer both as monotherapy or following platinum-based chemotherapy. Increased cytotoxicity and anti-tumor activity following treatment with olaparib were noted in cell lines and mouse tumor models with deficiencies in BRCA. In vitro studies have shown that olaparib-induced cytotoxicity may involve inhibition of PARP enzymatic activity and increased formation of PARP-DNA complex, resulting in disruption of cellular homeostasis and cell death.
TargetKindPharmacological actionActionsOrganismUniProt ID
Poly [ADP-ribose] polymerase 1Proteinyes
inhibitor
HumanP09874 details
Poly [ADP-ribose] polymerase 2Proteinyes
Inhibitor
HumanQ9UGN5 details
Poly [ADP-ribose] polymerase 3Proteinyes
Inhibitor
HumanQ9Y6F1 details
Related Articles
AbsorptionPeak plasma concentrations achieved typically between 1 to 3 hours following oral administration of olaparib in capsule formulation.
Volume of distribution

167 +/-196 L following a single dose of 400mg olaparib.

Protein bindingApproximately 82%.
Metabolism

Primarily CYP3A4 in vitro.

Route of elimination44% via the urine and 42% via the feces.
Half life11.9 hours, standard deviation 4.8 hours.
Clearance

8.6 +/- 7.1L/h.

ToxicityThe most commonly reported side effects reported during clinical trials included cough, constipation, dysguesia, peripheral deem, back pain, dizziness, headache, urinary tract infection, dyspnea, and rash. Myelodysplastic syndrome/Acute Myeloid Leukemia (MDS/AML) was reported in 2% of patients with deleterious or suspected deleterious germline BRCA-mutated advanced cancers. The majority of cases were fatal and the duration of therapy with olaparib in patients who developed secondary cancers varied from <6 months to >2 years. Complete blood count should be tested at baseline and monthly following therapy initiation to monitor for MDS/AML. Pneumonitis, including fatal cases, occurred in <1% of patients treated with olaparib. Patients should be monitored for new or worsening respiratory symptoms such as dyspnea, fever, cough, or wheezing. Olaparib was found to be teratogenic and causes embryo-fetal toxicity in rats. It should therefore be avoided during pregnancy and its use should be a combined with an effective contraception during treatment.
Affected organismsNot Available
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
AbirateroneThe metabolism of Abiraterone can be decreased when combined with Olaparib.Approved
AcenocoumarolThe metabolism of Acenocoumarol can be decreased when combined with Olaparib.Approved
AcetaminophenThe metabolism of Acetaminophen can be decreased when combined with Olaparib.Approved
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Olaparib.Approved
AdinazolamThe metabolism of Adinazolam can be decreased when combined with Olaparib.Approved
AlbendazoleThe metabolism of Albendazole can be decreased when combined with Olaparib.Approved, Vet Approved
AlclometasoneThe metabolism of Alclometasone can be decreased when combined with Olaparib.Approved
AlfentanilThe metabolism of Alfentanil can be decreased when combined with Olaparib.Approved, Illicit
AlfuzosinThe metabolism of Alfuzosin can be decreased when combined with Olaparib.Approved, Investigational
AliskirenThe metabolism of Aliskiren can be decreased when combined with Olaparib.Approved, Investigational
AllylestrenolThe metabolism of Allylestrenol can be decreased when combined with Olaparib.Approved
AlmotriptanThe metabolism of Almotriptan can be decreased when combined with Olaparib.Approved, Investigational
AlogliptinThe metabolism of Alogliptin can be decreased when combined with Olaparib.Approved
AlosetronThe metabolism of Alosetron can be decreased when combined with Olaparib.Approved, Withdrawn
AlprazolamThe metabolism of Alprazolam can be decreased when combined with Olaparib.Approved, Illicit, Investigational
AmbrisentanThe metabolism of Ambrisentan can be decreased when combined with Olaparib.Approved, Investigational
AmbroxolThe metabolism of Ambroxol can be decreased when combined with Olaparib.Approved
AminophenazoneThe metabolism of Aminophenazone can be decreased when combined with Olaparib.Approved, Withdrawn
AminophyllineThe metabolism of Aminophylline can be decreased when combined with Olaparib.Approved
AmiodaroneThe serum concentration of Olaparib can be increased when it is combined with Amiodarone.Approved, Investigational
AmitriptylineThe metabolism of Amitriptyline can be decreased when combined with Olaparib.Approved
AmlodipineThe metabolism of Amlodipine can be decreased when combined with Olaparib.Approved
AmprenavirThe metabolism of Amprenavir can be decreased when combined with Olaparib.Approved
AntipyrineThe metabolism of Antipyrine can be decreased when combined with Olaparib.Approved
AnvirzelAnvirzel may decrease the cardiotoxic activities of Olaparib.Investigational
ApixabanThe serum concentration of Apixaban can be increased when it is combined with Olaparib.Approved
ApremilastThe metabolism of Apremilast can be decreased when combined with Olaparib.Approved, Investigational
AprepitantThe serum concentration of Olaparib can be increased when it is combined with Aprepitant.Approved, Investigational
ArgatrobanThe metabolism of Argatroban can be decreased when combined with Olaparib.Approved, Investigational
AripiprazoleThe serum concentration of Aripiprazole can be increased when it is combined with Olaparib.Approved, Investigational
ArtemetherThe metabolism of Artemether can be decreased when combined with Olaparib.Approved
AsenapineThe metabolism of Asenapine can be decreased when combined with Olaparib.Approved
AstemizoleThe metabolism of Astemizole can be decreased when combined with Olaparib.Approved, Withdrawn
AtazanavirThe serum concentration of Olaparib can be increased when it is combined with Atazanavir.Approved, Investigational
AtomoxetineThe serum concentration of Olaparib can be increased when it is combined with Atomoxetine.Approved
AtorvastatinThe metabolism of Atorvastatin can be decreased when combined with Olaparib.Approved
AvanafilThe serum concentration of Avanafil can be increased when it is combined with Olaparib.Approved
AxitinibThe metabolism of Axitinib can be decreased when combined with Olaparib.Approved, Investigational
AzelastineThe metabolism of Azelastine can be decreased when combined with Olaparib.Approved
AzithromycinThe metabolism of Azithromycin can be decreased when combined with Olaparib.Approved
BanoxantroneThe metabolism of Banoxantrone can be decreased when combined with Olaparib.Investigational
BcgThe therapeutic efficacy of Bcg can be decreased when used in combination with Olaparib.Investigational
BedaquilineThe metabolism of Bedaquiline can be decreased when combined with Olaparib.Approved
BenzphetamineThe metabolism of Benzphetamine can be decreased when combined with Olaparib.Approved, Illicit
Benzyl alcoholThe metabolism of Benzyl alcohol can be decreased when combined with Olaparib.Approved
BevacizumabBevacizumab may increase the cardiotoxic activities of Olaparib.Approved, Investigational
BexaroteneThe serum concentration of Olaparib can be decreased when it is combined with Bexarotene.Approved, Investigational
BezafibrateThe metabolism of Bezafibrate can be decreased when combined with Olaparib.Approved
BicalutamideThe metabolism of Bicalutamide can be decreased when combined with Olaparib.Approved
BisoprololThe metabolism of Bisoprolol can be decreased when combined with Olaparib.Approved
BoceprevirThe serum concentration of Olaparib can be increased when it is combined with Boceprevir.Approved
BortezomibThe serum concentration of Olaparib can be increased when it is combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Olaparib can be decreased when it is combined with Bosentan.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Olaparib.Approved
Brentuximab vedotinThe metabolism of Brentuximab vedotin can be decreased when combined with Olaparib.Approved
BrexpiprazoleThe serum concentration of Brexpiprazole can be increased when it is combined with Olaparib.Approved
BrinzolamideThe metabolism of Brinzolamide can be decreased when combined with Olaparib.Approved
BromazepamThe metabolism of Bromazepam can be decreased when combined with Olaparib.Approved, Illicit
BromocriptineThe metabolism of Bromocriptine can be decreased when combined with Olaparib.Approved, Investigational
BrompheniramineThe metabolism of Brompheniramine can be decreased when combined with Olaparib.Approved
BudesonideThe serum concentration of Budesonide can be increased when it is combined with Olaparib.Approved
BudesonideThe metabolism of Budesonide can be decreased when combined with Olaparib.Approved
BupivacaineThe metabolism of Bupivacaine can be decreased when combined with Olaparib.Approved, Investigational
BuprenorphineThe metabolism of Buprenorphine can be decreased when combined with Olaparib.Approved, Illicit, Investigational, Vet Approved
BupropionThe metabolism of Bupropion can be decreased when combined with Olaparib.Approved
BuspironeThe metabolism of Buspirone can be decreased when combined with Olaparib.Approved, Investigational
BusulfanThe metabolism of Busulfan can be decreased when combined with Olaparib.Approved, Investigational
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Olaparib.Approved
CabergolineThe metabolism of Cabergoline can be decreased when combined with Olaparib.Approved
CabozantinibThe metabolism of Cabozantinib can be decreased when combined with Olaparib.Approved
CaffeineThe metabolism of Caffeine can be decreased when combined with Olaparib.Approved
CalcitriolThe metabolism of Calcitriol can be decreased when combined with Olaparib.Approved, Nutraceutical
CanagliflozinThe metabolism of Canagliflozin can be decreased when combined with Olaparib.Approved
CarbamazepineThe serum concentration of Olaparib can be decreased when it is combined with Carbamazepine.Approved, Investigational
CarbinoxamineThe metabolism of Carbinoxamine can be decreased when combined with Olaparib.Approved
CariprazineThe metabolism of Cariprazine can be decreased when combined with Olaparib.Approved
CarvedilolThe metabolism of Carvedilol can be decreased when combined with Olaparib.Approved, Investigational
CelecoxibThe metabolism of Celecoxib can be decreased when combined with Olaparib.Approved, Investigational
CeliprololThe metabolism of Celiprolol can be decreased when combined with Olaparib.Approved, Investigational
CephalexinThe metabolism of Cephalexin can be decreased when combined with Olaparib.Approved, Vet Approved
CeritinibThe serum concentration of Olaparib can be increased when it is combined with Ceritinib.Approved
CerivastatinThe metabolism of Cerivastatin can be decreased when combined with Olaparib.Withdrawn
CevimelineThe metabolism of Cevimeline can be decreased when combined with Olaparib.Approved
Chenodeoxycholic acidThe metabolism of Chenodeoxycholic acid can be decreased when combined with Olaparib.Approved
ChlordiazepoxideThe metabolism of Chlordiazepoxide can be decreased when combined with Olaparib.Approved, Illicit
ChloroquineThe metabolism of Chloroquine can be decreased when combined with Olaparib.Approved, Vet Approved
ChlorphenamineThe metabolism of Chlorphenamine can be decreased when combined with Olaparib.Approved
ChlorpromazineThe metabolism of Chlorpromazine can be decreased when combined with Olaparib.Approved, Vet Approved
ChlorzoxazoneThe metabolism of Chlorzoxazone can be decreased when combined with Olaparib.Approved
CholecalciferolThe metabolism of Cholecalciferol can be decreased when combined with Olaparib.Approved, Nutraceutical
CiclesonideThe metabolism of Ciclesonide can be decreased when combined with Olaparib.Approved, Investigational
CilostazolThe serum concentration of Cilostazol can be increased when it is combined with Olaparib.Approved
CinacalcetThe metabolism of Cinacalcet can be decreased when combined with Olaparib.Approved
CisaprideThe metabolism of Cisapride can be decreased when combined with Olaparib.Approved, Investigational, Withdrawn
CitalopramThe metabolism of Citalopram can be decreased when combined with Olaparib.Approved
ClarithromycinThe serum concentration of Olaparib can be increased when it is combined with Clarithromycin.Approved
ClemastineThe serum concentration of Olaparib can be increased when it is combined with Clemastine.Approved
ClindamycinThe metabolism of Clindamycin can be decreased when combined with Olaparib.Approved, Vet Approved
ClobazamThe metabolism of Clobazam can be decreased when combined with Olaparib.Approved, Illicit
ClofazimineThe metabolism of Clofazimine can be decreased when combined with Olaparib.Approved, Investigational
ClofibrateThe metabolism of Clofibrate can be decreased when combined with Olaparib.Approved
clomethiazoleThe metabolism of clomethiazole can be decreased when combined with Olaparib.Investigational
ClomipramineThe metabolism of Clomipramine can be decreased when combined with Olaparib.Approved, Vet Approved
ClonazepamThe metabolism of Clonazepam can be decreased when combined with Olaparib.Approved, Illicit
ClonidineThe metabolism of Clonidine can be decreased when combined with Olaparib.Approved
ClopidogrelThe metabolism of Clopidogrel can be decreased when combined with Olaparib.Approved, Nutraceutical
ClorazepateThe metabolism of Clorazepate can be decreased when combined with Olaparib.Approved, Illicit
ClotiazepamThe metabolism of Clotiazepam can be decreased when combined with Olaparib.Approved, Illicit
ClotrimazoleThe serum concentration of Olaparib can be increased when it is combined with Clotrimazole.Approved, Vet Approved
ClozapineThe risk or severity of adverse effects can be increased when Olaparib is combined with Clozapine.Approved
CobicistatThe serum concentration of Olaparib can be increased when it is combined with Cobicistat.Approved
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Olaparib.Approved
CocaineThe metabolism of Cocaine can be decreased when combined with Olaparib.Approved, Illicit
CodeineThe metabolism of Codeine can be decreased when combined with Olaparib.Approved, Illicit
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Olaparib.Approved
ConivaptanThe serum concentration of Olaparib can be increased when it is combined with Conivaptan.Approved, Investigational
Conjugated Equine EstrogensThe metabolism of Conjugated Equine Estrogens can be decreased when combined with Olaparib.Approved
Cortisone acetateThe metabolism of Cortisone acetate can be decreased when combined with Olaparib.Approved
CrizotinibThe serum concentration of Olaparib can be increased when it is combined with Crizotinib.Approved
CyclobenzaprineThe metabolism of Cyclobenzaprine can be decreased when combined with Olaparib.Approved
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Olaparib.Approved, Investigational
CyclosporineThe serum concentration of Olaparib can be increased when it is combined with Cyclosporine.Approved, Investigational, Vet Approved
CytarabineThe metabolism of Cytarabine can be decreased when combined with Olaparib.Approved, Investigational
DabrafenibThe serum concentration of Olaparib can be decreased when it is combined with Dabrafenib.Approved
DaclatasvirThe metabolism of Daclatasvir can be decreased when combined with Olaparib.Approved
DantroleneThe metabolism of Dantrolene can be decreased when combined with Olaparib.Approved
DapagliflozinThe metabolism of Dapagliflozin can be decreased when combined with Olaparib.Approved
DapoxetineThe serum concentration of Dapoxetine can be increased when it is combined with Olaparib.Investigational
DapsoneThe metabolism of Dapsone can be decreased when combined with Olaparib.Approved, Investigational
DarifenacinThe metabolism of Darifenacin can be decreased when combined with Olaparib.Approved, Investigational
DarunavirThe serum concentration of Olaparib can be increased when it is combined with Darunavir.Approved
DasabuvirThe metabolism of Dasabuvir can be decreased when combined with Olaparib.Approved
DasatinibThe serum concentration of Olaparib can be increased when it is combined with Dasatinib.Approved, Investigational
DaunorubicinThe metabolism of Daunorubicin can be decreased when combined with Olaparib.Approved
DeferasiroxThe serum concentration of Olaparib can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe serum concentration of Olaparib can be increased when it is combined with Delavirdine.Approved
DeslanosideDeslanoside may decrease the cardiotoxic activities of Olaparib.Approved
DesvenlafaxineThe metabolism of Desvenlafaxine can be decreased when combined with Olaparib.Approved
DexamethasoneThe serum concentration of Olaparib can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DextromethorphanThe metabolism of Dextromethorphan can be decreased when combined with Olaparib.Approved
DextropropoxypheneThe metabolism of Dextropropoxyphene can be decreased when combined with Olaparib.Approved, Illicit, Withdrawn
DiazepamThe metabolism of Diazepam can be decreased when combined with Olaparib.Approved, Illicit, Vet Approved
DiclofenacThe metabolism of Diclofenac can be decreased when combined with Olaparib.Approved, Vet Approved
DigitoxinDigitoxin may decrease the cardiotoxic activities of Olaparib.Approved
DigoxinDigoxin may decrease the cardiotoxic activities of Olaparib.Approved
DihydrocodeineThe metabolism of Dihydrocodeine can be decreased when combined with Olaparib.Approved, Illicit
DihydroergotamineThe serum concentration of Olaparib can be increased when it is combined with Dihydroergotamine.Approved
DiltiazemThe serum concentration of Olaparib can be increased when it is combined with Diltiazem.Approved
DisopyramideThe metabolism of Disopyramide can be decreased when combined with Olaparib.Approved
DisulfiramThe metabolism of Disulfiram can be decreased when combined with Olaparib.Approved
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Olaparib.Approved, Investigational
DofetilideThe serum concentration of Dofetilide can be increased when it is combined with Olaparib.Approved
DolasetronThe metabolism of Dolasetron can be decreased when combined with Olaparib.Approved
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Olaparib.Approved, Investigational, Vet Approved
DonepezilThe metabolism of Donepezil can be decreased when combined with Olaparib.Approved
DorzolamideThe metabolism of Dorzolamide can be decreased when combined with Olaparib.Approved
DoxepinThe metabolism of Doxepin can be decreased when combined with Olaparib.Approved
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Olaparib.Approved, Investigational
DoxorubicinThe metabolism of Doxorubicin can be decreased when combined with Olaparib.Approved, Investigational
DoxycyclineThe serum concentration of Olaparib can be increased when it is combined with Doxycycline.Approved, Investigational, Vet Approved
DronabinolThe serum concentration of Dronabinol can be increased when it is combined with Olaparib.Approved, Illicit
DronedaroneThe serum concentration of Olaparib can be increased when it is combined with Dronedarone.Approved
DutasterideThe metabolism of Dutasteride can be decreased when combined with Olaparib.Approved, Investigational
EfavirenzThe serum concentration of Olaparib can be decreased when it is combined with Efavirenz.Approved, Investigational
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Olaparib.Approved, Investigational
EliglustatThe serum concentration of Eliglustat can be increased when it is combined with Olaparib.Approved
ElvitegravirThe metabolism of Elvitegravir can be decreased when combined with Olaparib.Approved
EnalaprilThe metabolism of Enalapril can be decreased when combined with Olaparib.Approved, Vet Approved
EnzalutamideThe serum concentration of Olaparib can be decreased when it is combined with Enzalutamide.Approved
EpinastineThe metabolism of Epinastine can be decreased when combined with Olaparib.Approved, Investigational
EplerenoneThe serum concentration of Eplerenone can be increased when it is combined with Olaparib.Approved
ErgocalciferolThe metabolism of Ergocalciferol can be decreased when combined with Olaparib.Approved, Nutraceutical
Ergoloid mesylateThe metabolism of Ergoloid mesylate can be decreased when combined with Olaparib.Approved
ErgonovineThe metabolism of Ergonovine can be decreased when combined with Olaparib.Approved
ErgotamineThe metabolism of Ergotamine can be decreased when combined with Olaparib.Approved
ErlotinibThe metabolism of Erlotinib can be decreased when combined with Olaparib.Approved, Investigational
ErythromycinThe serum concentration of Olaparib can be increased when it is combined with Erythromycin.Approved, Vet Approved
EscitalopramThe metabolism of Escitalopram can be decreased when combined with Olaparib.Approved, Investigational
Eslicarbazepine acetateThe serum concentration of Olaparib can be decreased when it is combined with Eslicarbazepine acetate.Approved
EsomeprazoleThe metabolism of Esomeprazole can be decreased when combined with Olaparib.Approved, Investigational
EstazolamThe metabolism of Estazolam can be decreased when combined with Olaparib.Approved, Illicit
EstradiolThe metabolism of Estradiol can be decreased when combined with Olaparib.Approved, Investigational, Vet Approved
Estradiol valerate/DienogestThe metabolism of Estradiol valerate/Dienogest can be decreased when combined with Olaparib.Approved
EstramustineThe metabolism of Estramustine can be decreased when combined with Olaparib.Approved
EstroneThe metabolism of Estrone can be decreased when combined with Olaparib.Approved
Estrone sulfateThe metabolism of Estrone sulfate can be decreased when combined with Olaparib.Approved
EszopicloneThe metabolism of Eszopiclone can be decreased when combined with Olaparib.Approved
EthanolThe metabolism of Ethanol can be decreased when combined with Olaparib.Approved
Ethinyl EstradiolThe metabolism of Ethinyl Estradiol can be decreased when combined with Olaparib.Approved
EthosuximideThe metabolism of Ethosuximide can be decreased when combined with Olaparib.Approved
EthylmorphineThe metabolism of Ethylmorphine can be decreased when combined with Olaparib.Approved, Illicit
EtonogestrelThe metabolism of Etonogestrel can be decreased when combined with Olaparib.Approved, Investigational
EtoposideThe metabolism of Etoposide can be decreased when combined with Olaparib.Approved
EtoricoxibThe metabolism of Etoricoxib can be decreased when combined with Olaparib.Approved, Investigational
EtravirineThe serum concentration of Olaparib can be decreased when it is combined with Etravirine.Approved
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Olaparib.Approved
ExemestaneThe metabolism of Exemestane can be decreased when combined with Olaparib.Approved, Investigational
FamciclovirThe metabolism of Famciclovir can be decreased when combined with Olaparib.Approved
FelbamateThe metabolism of Felbamate can be decreased when combined with Olaparib.Approved
FelodipineThe metabolism of Felodipine can be decreased when combined with Olaparib.Approved, Investigational
FenofibrateThe metabolism of Fenofibrate can be decreased when combined with Olaparib.Approved
FentanylThe serum concentration of Fentanyl can be increased when it is combined with Olaparib.Approved, Illicit, Investigational, Vet Approved
FesoterodineThe metabolism of Fesoterodine can be decreased when combined with Olaparib.Approved
FinasterideThe metabolism of Finasteride can be decreased when combined with Olaparib.Approved
FingolimodThe metabolism of Fingolimod can be decreased when combined with Olaparib.Approved, Investigational
FlibanserinThe serum concentration of Flibanserin can be increased when it is combined with Olaparib.Approved
FluconazoleThe serum concentration of Olaparib can be increased when it is combined with Fluconazole.Approved
FlunisolideThe metabolism of Flunisolide can be decreased when combined with Olaparib.Approved, Investigational
FlunitrazepamThe metabolism of Flunitrazepam can be decreased when combined with Olaparib.Approved, Illicit
FluorometholoneThe metabolism of Fluorometholone can be decreased when combined with Olaparib.Approved
FluoxetineThe metabolism of Fluoxetine can be decreased when combined with Olaparib.Approved, Vet Approved
FlurazepamThe metabolism of Flurazepam can be decreased when combined with Olaparib.Approved, Illicit
FlutamideThe metabolism of Flutamide can be decreased when combined with Olaparib.Approved
Fluticasone furoateThe metabolism of Fluticasone furoate can be decreased when combined with Olaparib.Approved
Fluticasone PropionateThe metabolism of Fluticasone Propionate can be decreased when combined with Olaparib.Approved
FluvastatinThe metabolism of Fluvastatin can be decreased when combined with Olaparib.Approved
FluvoxamineThe serum concentration of Olaparib can be increased when it is combined with Fluvoxamine.Approved, Investigational
FosamprenavirThe serum concentration of Olaparib can be increased when it is combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Olaparib can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe serum concentration of Olaparib can be decreased when it is combined with Fosphenytoin.Approved
FulvestrantThe metabolism of Fulvestrant can be decreased when combined with Olaparib.Approved, Investigational
Fusidic AcidThe serum concentration of Olaparib can be increased when it is combined with Fusidic Acid.Approved
GalantamineThe metabolism of Galantamine can be decreased when combined with Olaparib.Approved
GefitinibThe metabolism of Gefitinib can be decreased when combined with Olaparib.Approved, Investigational
GemfibrozilThe metabolism of Gemfibrozil can be decreased when combined with Olaparib.Approved
GlipizideThe metabolism of Glipizide can be decreased when combined with Olaparib.Approved
GlyburideThe metabolism of Glyburide can be decreased when combined with Olaparib.Approved
GranisetronThe metabolism of Granisetron can be decreased when combined with Olaparib.Approved, Investigational
GrepafloxacinThe metabolism of Grepafloxacin can be decreased when combined with Olaparib.Withdrawn
GuanfacineThe metabolism of Guanfacine can be decreased when combined with Olaparib.Approved, Investigational
HalofantrineThe serum concentration of Halofantrine can be increased when it is combined with Olaparib.Approved
HaloperidolThe metabolism of Haloperidol can be decreased when combined with Olaparib.Approved
HalothaneThe metabolism of Halothane can be decreased when combined with Olaparib.Approved, Vet Approved
HexobarbitalThe metabolism of Hexobarbital can be decreased when combined with Olaparib.Approved
Histamine PhosphateThe metabolism of Histamine Phosphate can be decreased when combined with Olaparib.Approved
HydrocodoneThe serum concentration of Hydrocodone can be increased when it is combined with Olaparib.Approved, Illicit
HydrocortisoneThe metabolism of Hydrocortisone can be decreased when combined with Olaparib.Approved, Vet Approved
HydromorphoneThe metabolism of Hydromorphone can be decreased when combined with Olaparib.Approved, Illicit
Hydroxyprogesterone caproateThe metabolism of Hydroxyprogesterone caproate can be decreased when combined with Olaparib.Approved
IbrutinibThe serum concentration of Ibrutinib can be increased when it is combined with Olaparib.Approved
IdelalisibThe serum concentration of Olaparib can be increased when it is combined with Idelalisib.Approved
IfosfamideThe serum concentration of the active metabolites of Ifosfamide can be reduced when Ifosfamide is used in combination with Olaparib resulting in a loss in efficacy.Approved
IloperidoneThe metabolism of Iloperidone can be decreased when combined with Olaparib.Approved
ImatinibThe serum concentration of Olaparib can be increased when it is combined with Imatinib.Approved
ImipramineThe metabolism of Imipramine can be decreased when combined with Olaparib.Approved
ImiquimodThe metabolism of Imiquimod can be decreased when combined with Olaparib.Approved, Investigational
IndacaterolThe metabolism of Indacaterol can be decreased when combined with Olaparib.Approved
IndapamideThe metabolism of Indapamide can be decreased when combined with Olaparib.Approved
IndinavirThe serum concentration of Olaparib can be increased when it is combined with Indinavir.Approved
Ipratropium bromideThe metabolism of Ipratropium bromide can be decreased when combined with Olaparib.Approved
IrinotecanThe metabolism of Irinotecan can be decreased when combined with Olaparib.Approved, Investigational
IsavuconazoniumThe serum concentration of Olaparib can be increased when it is combined with Isavuconazonium.Approved, Investigational
Isosorbide DinitrateThe metabolism of Isosorbide Dinitrate can be decreased when combined with Olaparib.Approved
Isosorbide MononitrateThe metabolism of Isosorbide Mononitrate can be decreased when combined with Olaparib.Approved
IsradipineThe serum concentration of Olaparib can be increased when it is combined with Isradipine.Approved
ItraconazoleThe serum concentration of Olaparib can be increased when it is combined with Itraconazole.Approved, Investigational
IvabradineThe serum concentration of Ivabradine can be increased when it is combined with Olaparib.Approved
IvacaftorThe serum concentration of Ivacaftor can be increased when it is combined with Olaparib.Approved
IvermectinThe metabolism of Ivermectin can be decreased when combined with Olaparib.Approved, Vet Approved
IxabepiloneThe metabolism of Ixabepilone can be decreased when combined with Olaparib.Approved, Investigational
IxazomibThe metabolism of Ixazomib can be decreased when combined with Olaparib.Approved
KetamineThe metabolism of Ketamine can be decreased when combined with Olaparib.Approved, Vet Approved
KetazolamThe metabolism of Ketazolam can be decreased when combined with Olaparib.Approved
KetobemidoneThe metabolism of Ketobemidone can be decreased when combined with Olaparib.Approved
KetoconazoleThe serum concentration of Olaparib can be increased when it is combined with Ketoconazole.Approved, Investigational
LansoprazoleThe metabolism of Lansoprazole can be decreased when combined with Olaparib.Approved, Investigational
LapatinibThe metabolism of Lapatinib can be decreased when combined with Olaparib.Approved, Investigational
LaquinimodThe metabolism of Laquinimod can be decreased when combined with Olaparib.Investigational
LenvatinibThe metabolism of Lenvatinib can be decreased when combined with Olaparib.Approved
LercanidipineThe metabolism of Lercanidipine can be decreased when combined with Olaparib.Approved, Investigational
LetrozoleThe metabolism of Letrozole can be decreased when combined with Olaparib.Approved, Investigational
LevobupivacaineThe metabolism of Levobupivacaine can be decreased when combined with Olaparib.Approved
LevocetirizineThe metabolism of Levocetirizine can be decreased when combined with Olaparib.Approved
Levomethadyl AcetateThe metabolism of Levomethadyl Acetate can be decreased when combined with Olaparib.Approved
LevomilnacipranThe metabolism of Levomilnacipran can be decreased when combined with Olaparib.Approved
LevonorgestrelThe metabolism of Levonorgestrel can be decreased when combined with Olaparib.Approved, Investigational
LevothyroxineThe metabolism of Levothyroxine can be decreased when combined with Olaparib.Approved
LidocaineThe metabolism of Lidocaine can be decreased when combined with Olaparib.Approved, Vet Approved
LisurideThe metabolism of Lisuride can be decreased when combined with Olaparib.Approved
LomitapideThe serum concentration of Lomitapide can be increased when it is combined with Olaparib.Approved
LoperamideThe metabolism of Loperamide can be decreased when combined with Olaparib.Approved
LopinavirThe serum concentration of Olaparib can be increased when it is combined with Lopinavir.Approved
LoratadineThe metabolism of Loratadine can be decreased when combined with Olaparib.Approved
LorcaserinThe metabolism of Lorcaserin can be decreased when combined with Olaparib.Approved
LosartanThe metabolism of Losartan can be decreased when combined with Olaparib.Approved
LovastatinThe serum concentration of Olaparib can be increased when it is combined with Lovastatin.Approved, Investigational
LuliconazoleThe serum concentration of Olaparib can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Olaparib can be decreased when it is combined with Lumacaftor.Approved
LumefantrineThe metabolism of Lumefantrine can be decreased when combined with Olaparib.Approved
LurasidoneThe serum concentration of Lurasidone can be increased when it is combined with Olaparib.Approved
MacitentanThe metabolism of Macitentan can be decreased when combined with Olaparib.Approved
MaravirocThe metabolism of Maraviroc can be decreased when combined with Olaparib.Approved, Investigational
MebendazoleThe metabolism of Mebendazole can be decreased when combined with Olaparib.Approved, Vet Approved
Medroxyprogesterone acetateThe metabolism of Medroxyprogesterone acetate can be decreased when combined with Olaparib.Approved, Investigational
MefloquineThe metabolism of Mefloquine can be decreased when combined with Olaparib.Approved
MeloxicamThe metabolism of Meloxicam can be decreased when combined with Olaparib.Approved, Vet Approved
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Olaparib.Withdrawn
MethadoneThe metabolism of Methadone can be decreased when combined with Olaparib.Approved
MethaqualoneThe metabolism of Methaqualone can be decreased when combined with Olaparib.Illicit, Withdrawn
MethoxsalenThe metabolism of Methoxsalen can be decreased when combined with Olaparib.Approved
MethoxyfluraneThe metabolism of Methoxyflurane can be decreased when combined with Olaparib.Approved, Vet Approved
MethylprednisoloneThe metabolism of Methylprednisolone can be decreased when combined with Olaparib.Approved, Vet Approved
MethyltestosteroneThe metabolism of Methyltestosterone can be decreased when combined with Olaparib.Approved
MetronidazoleThe metabolism of Metronidazole can be decreased when combined with Olaparib.Approved
MexiletineThe metabolism of Mexiletine can be decreased when combined with Olaparib.Approved
MianserinThe metabolism of Mianserin can be decreased when combined with Olaparib.Approved
MibefradilThe metabolism of Mibefradil can be decreased when combined with Olaparib.Withdrawn
MiconazoleThe metabolism of Miconazole can be decreased when combined with Olaparib.Approved, Investigational, Vet Approved
MidazolamThe metabolism of Midazolam can be decreased when combined with Olaparib.Approved, Illicit
MifepristoneThe serum concentration of Olaparib can be increased when it is combined with Mifepristone.Approved, Investigational
MirabegronThe metabolism of Mirabegron can be decreased when combined with Olaparib.Approved
MirtazapineThe metabolism of Mirtazapine can be decreased when combined with Olaparib.Approved
MitotaneThe serum concentration of Olaparib can be decreased when it is combined with Mitotane.Approved
ModafinilThe serum concentration of Olaparib can be decreased when it is combined with Modafinil.Approved, Investigational
MontelukastThe metabolism of Montelukast can be decreased when combined with Olaparib.Approved
MorphineThe metabolism of Morphine can be decreased when combined with Olaparib.Approved, Investigational
Mycophenolate mofetilThe metabolism of Mycophenolate mofetil can be decreased when combined with Olaparib.Approved, Investigational
NafcillinThe serum concentration of Olaparib can be decreased when it is combined with Nafcillin.Approved
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Olaparib.Approved
NaloxoneThe metabolism of Naloxone can be decreased when combined with Olaparib.Approved, Vet Approved
NateglinideThe metabolism of Nateglinide can be decreased when combined with Olaparib.Approved, Investigational
NefazodoneThe serum concentration of Olaparib can be increased when it is combined with Nefazodone.Approved, Withdrawn
NelfinavirThe serum concentration of Olaparib can be increased when it is combined with Nelfinavir.Approved
NetupitantThe serum concentration of Olaparib can be increased when it is combined with Netupitant.Approved
NevirapineThe serum concentration of Olaparib can be increased when it is combined with Nevirapine.Approved
NicardipineThe metabolism of Nicardipine can be decreased when combined with Olaparib.Approved
NicotineThe metabolism of Nicotine can be decreased when combined with Olaparib.Approved
NifedipineThe metabolism of Nifedipine can be decreased when combined with Olaparib.Approved
NilotinibThe serum concentration of Olaparib can be increased when it is combined with Nilotinib.Approved, Investigational
NilvadipineThe metabolism of Nilvadipine can be decreased when combined with Olaparib.Approved
NimodipineThe serum concentration of Nimodipine can be increased when it is combined with Olaparib.Approved
NisoldipineThe metabolism of Nisoldipine can be decreased when combined with Olaparib.Approved
NitrazepamThe metabolism of Nitrazepam can be decreased when combined with Olaparib.Approved
NitrendipineThe metabolism of Nitrendipine can be decreased when combined with Olaparib.Approved
NorethisteroneThe metabolism of Norethisterone can be decreased when combined with Olaparib.Approved
NorgestrelThe metabolism of Norgestrel can be decreased when combined with Olaparib.Approved
NortriptylineThe metabolism of Nortriptyline can be decreased when combined with Olaparib.Approved
OlopatadineThe metabolism of Olopatadine can be decreased when combined with Olaparib.Approved
OmeprazoleThe metabolism of Omeprazole can be decreased when combined with Olaparib.Approved, Investigational, Vet Approved
OndansetronThe metabolism of Ondansetron can be decreased when combined with Olaparib.Approved
OrphenadrineThe metabolism of Orphenadrine can be decreased when combined with Olaparib.Approved
OsimertinibThe serum concentration of Olaparib can be increased when it is combined with Osimertinib.Approved
OspemifeneThe metabolism of Ospemifene can be decreased when combined with Olaparib.Approved
OuabainOuabain may decrease the cardiotoxic activities of Olaparib.Approved
OxazepamThe metabolism of Oxazepam can be decreased when combined with Olaparib.Approved
OxybutyninThe metabolism of Oxybutynin can be decreased when combined with Olaparib.Approved, Investigational
OxycodoneThe risk or severity of adverse effects can be increased when Olaparib is combined with Oxycodone.Approved, Illicit, Investigational
OxymorphoneThe metabolism of Oxymorphone can be decreased when combined with Olaparib.Approved, Investigational, Vet Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Olaparib.Approved, Vet Approved
PalbociclibThe serum concentration of Olaparib can be increased when it is combined with Palbociclib.Approved
PalonosetronThe metabolism of Palonosetron can be decreased when combined with Olaparib.Approved, Investigational
PanobinostatThe metabolism of Panobinostat can be decreased when combined with Olaparib.Approved, Investigational
PantoprazoleThe metabolism of Pantoprazole can be decreased when combined with Olaparib.Approved
ParamethadioneThe metabolism of Paramethadione can be decreased when combined with Olaparib.Approved
ParamethasoneThe metabolism of Paramethasone can be decreased when combined with Olaparib.Approved
ParecoxibThe metabolism of Parecoxib can be decreased when combined with Olaparib.Approved
ParicalcitolThe metabolism of Paricalcitol can be decreased when combined with Olaparib.Approved, Investigational
ParitaprevirThe metabolism of Paritaprevir can be decreased when combined with Olaparib.Approved
PazopanibThe metabolism of Pazopanib can be decreased when combined with Olaparib.Approved
PentamidineThe metabolism of Pentamidine can be decreased when combined with Olaparib.Approved
PentobarbitalThe serum concentration of Olaparib can be decreased when it is combined with Pentobarbital.Approved, Vet Approved
PerampanelThe metabolism of Perampanel can be decreased when combined with Olaparib.Approved
PergolideThe metabolism of Pergolide can be decreased when combined with Olaparib.Approved, Vet Approved, Withdrawn
PerhexilineThe metabolism of Perhexiline can be decreased when combined with Olaparib.Approved
PermethrinThe metabolism of Permethrin can be decreased when combined with Olaparib.Approved, Investigational
PerphenazineThe metabolism of Perphenazine can be decreased when combined with Olaparib.Approved
PethidineThe metabolism of Pethidine can be decreased when combined with Olaparib.Approved
PhenacetinThe metabolism of Phenacetin can be decreased when combined with Olaparib.Withdrawn
PhenobarbitalThe serum concentration of Olaparib can be decreased when it is combined with Phenobarbital.Approved
PhenoxybenzamineThe metabolism of Phenoxybenzamine can be decreased when combined with Olaparib.Approved
PhenprocoumonThe metabolism of Phenprocoumon can be decreased when combined with Olaparib.Approved
PhenytoinThe serum concentration of Olaparib can be decreased when it is combined with Phenytoin.Approved, Vet Approved
PilocarpineThe metabolism of Pilocarpine can be decreased when combined with Olaparib.Approved
PimecrolimusThe metabolism of Pimecrolimus can be decreased when combined with Olaparib.Approved, Investigational
PimozideThe serum concentration of Pimozide can be increased when it is combined with Olaparib.Approved
PinacidilThe metabolism of Pinacidil can be decreased when combined with Olaparib.Withdrawn
PioglitazoneThe metabolism of Pioglitazone can be decreased when combined with Olaparib.Approved, Investigational
PipotiazineThe metabolism of Pipotiazine can be decreased when combined with Olaparib.Approved
PodofiloxThe metabolism of Podofilox can be decreased when combined with Olaparib.Approved
PomalidomideThe metabolism of Pomalidomide can be decreased when combined with Olaparib.Approved
PonatinibThe metabolism of Ponatinib can be decreased when combined with Olaparib.Approved
PosaconazoleThe serum concentration of Olaparib can be increased when it is combined with Posaconazole.Approved, Investigational, Vet Approved
PrasteroneThe metabolism of Prasterone can be decreased when combined with Olaparib.Approved, Nutraceutical
PrasugrelThe metabolism of Prasugrel can be decreased when combined with Olaparib.Approved
PravastatinThe metabolism of Pravastatin can be decreased when combined with Olaparib.Approved
PrazepamThe metabolism of Prazepam can be decreased when combined with Olaparib.Approved, Illicit
PraziquantelThe metabolism of Praziquantel can be decreased when combined with Olaparib.Approved, Vet Approved
PrednisoloneThe metabolism of Prednisolone can be decreased when combined with Olaparib.Approved, Vet Approved
PrednisoneThe metabolism of Prednisone can be decreased when combined with Olaparib.Approved, Vet Approved
PrimaquineThe metabolism of Primaquine can be decreased when combined with Olaparib.Approved
PrimidoneThe serum concentration of Olaparib can be decreased when it is combined with Primidone.Approved, Vet Approved
ProchlorperazineThe metabolism of Prochlorperazine can be decreased when combined with Olaparib.Approved, Vet Approved
ProgesteroneThe metabolism of Progesterone can be decreased when combined with Olaparib.Approved, Vet Approved
ProguanilThe metabolism of Proguanil can be decreased when combined with Olaparib.Approved
PromazineThe metabolism of Promazine can be decreased when combined with Olaparib.Approved, Vet Approved
PropafenoneThe serum concentration of Propafenone can be increased when it is combined with Olaparib.Approved
PropofolThe metabolism of Propofol can be decreased when combined with Olaparib.Approved, Investigational, Vet Approved
PropranololThe metabolism of Propranolol can be decreased when combined with Olaparib.Approved, Investigational
PyrazinamideThe metabolism of Pyrazinamide can be decreased when combined with Olaparib.Approved
QuazepamThe metabolism of Quazepam can be decreased when combined with Olaparib.Approved, Illicit
QuetiapineThe metabolism of Quetiapine can be decreased when combined with Olaparib.Approved
QuinacrineThe metabolism of Quinacrine can be decreased when combined with Olaparib.Approved
QuinidineThe metabolism of Quinidine can be decreased when combined with Olaparib.Approved
QuinineThe metabolism of Quinine can be decreased when combined with Olaparib.Approved
RabeprazoleThe metabolism of Rabeprazole can be decreased when combined with Olaparib.Approved, Investigational
RaloxifeneThe metabolism of Raloxifene can be decreased when combined with Olaparib.Approved, Investigational
RamelteonThe metabolism of Ramelteon can be decreased when combined with Olaparib.Approved, Investigational
RanolazineThe serum concentration of Olaparib can be increased when it is combined with Ranolazine.Approved, Investigational
ReboxetineThe metabolism of Reboxetine can be decreased when combined with Olaparib.Approved, Investigational
RegorafenibThe metabolism of Regorafenib can be decreased when combined with Olaparib.Approved
RepaglinideThe metabolism of Repaglinide can be decreased when combined with Olaparib.Approved, Investigational
RetapamulinThe metabolism of Retapamulin can be decreased when combined with Olaparib.Approved
RifabutinThe serum concentration of Olaparib can be decreased when it is combined with Rifabutin.Approved
RifampicinThe serum concentration of Olaparib can be decreased when it is combined with Rifampicin.Approved
RifapentineThe serum concentration of Olaparib can be decreased when it is combined with Rifapentine.Approved
RilpivirineThe metabolism of Rilpivirine can be decreased when combined with Olaparib.Approved
RimonabantThe metabolism of Rimonabant can be decreased when combined with Olaparib.Approved, Investigational
RiociguatThe metabolism of Riociguat can be decreased when combined with Olaparib.Approved
RisperidoneThe metabolism of Risperidone can be decreased when combined with Olaparib.Approved, Investigational
RitonavirThe serum concentration of Olaparib can be increased when it is combined with Ritonavir.Approved, Investigational
RivaroxabanThe metabolism of Rivaroxaban can be decreased when combined with Olaparib.Approved
RofecoxibThe metabolism of Rofecoxib can be decreased when combined with Olaparib.Investigational, Withdrawn
RolapitantThe metabolism of Rolapitant can be decreased when combined with Olaparib.Approved
RomidepsinThe metabolism of Romidepsin can be decreased when combined with Olaparib.Approved, Investigational
RopiniroleThe metabolism of Ropinirole can be decreased when combined with Olaparib.Approved, Investigational
RopivacaineThe metabolism of Ropivacaine can be decreased when combined with Olaparib.Approved
RosuvastatinThe metabolism of Rosuvastatin can be decreased when combined with Olaparib.Approved
RotigotineThe metabolism of Rotigotine can be decreased when combined with Olaparib.Approved
RoxithromycinThe metabolism of Roxithromycin can be decreased when combined with Olaparib.Approved, Withdrawn
RuxolitinibThe metabolism of Ruxolitinib can be decreased when combined with Olaparib.Approved
SalmeterolThe serum concentration of Salmeterol can be increased when it is combined with Olaparib.Approved
SaquinavirThe serum concentration of Olaparib can be increased when it is combined with Saquinavir.Approved, Investigational
SaxagliptinThe serum concentration of Saxagliptin can be increased when it is combined with Olaparib.Approved
SelegilineThe metabolism of Selegiline can be decreased when combined with Olaparib.Approved, Investigational, Vet Approved
SelexipagThe metabolism of Selexipag can be decreased when combined with Olaparib.Approved
SeratrodastThe metabolism of Seratrodast can be decreased when combined with Olaparib.Approved, Investigational
SertindoleThe metabolism of Sertindole can be decreased when combined with Olaparib.Approved, Withdrawn
SertralineThe metabolism of Sertraline can be decreased when combined with Olaparib.Approved
SevofluraneThe metabolism of Sevoflurane can be decreased when combined with Olaparib.Approved, Vet Approved
SibutramineThe metabolism of Sibutramine can be decreased when combined with Olaparib.Approved, Illicit, Investigational, Withdrawn
SildenafilThe serum concentration of Olaparib can be increased when it is combined with Sildenafil.Approved, Investigational
SilodosinThe metabolism of Silodosin can be decreased when combined with Olaparib.Approved
SiltuximabThe serum concentration of Olaparib can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Simeprevir can be increased when it is combined with Olaparib.Approved
SimvastatinThe metabolism of Simvastatin can be decreased when combined with Olaparib.Approved
SirolimusThe metabolism of Sirolimus can be decreased when combined with Olaparib.Approved, Investigational
SitagliptinThe metabolism of Sitagliptin can be decreased when combined with Olaparib.Approved, Investigational
SolifenacinThe metabolism of Solifenacin can be decreased when combined with Olaparib.Approved
SonidegibThe serum concentration of Sonidegib can be increased when it is combined with Olaparib.Approved, Investigational
SorafenibThe metabolism of Sorafenib can be decreased when combined with Olaparib.Approved, Investigational
SpiramycinThe metabolism of Spiramycin can be decreased when combined with Olaparib.Approved
St. John's WortThe serum concentration of Olaparib can be decreased when it is combined with St. John&#39;s Wort.Nutraceutical
StiripentolThe serum concentration of Olaparib can be increased when it is combined with Stiripentol.Approved
SufentanilThe metabolism of Sufentanil can be decreased when combined with Olaparib.Approved, Investigational
SulfadiazineThe metabolism of Sulfadiazine can be decreased when combined with Olaparib.Approved, Vet Approved
SulfamethoxazoleThe metabolism of Sulfamethoxazole can be decreased when combined with Olaparib.Approved
SulfinpyrazoneThe metabolism of Sulfinpyrazone can be decreased when combined with Olaparib.Approved
SulfisoxazoleThe serum concentration of Olaparib can be increased when it is combined with Sulfisoxazole.Approved, Vet Approved
SunitinibThe metabolism of Sunitinib can be decreased when combined with Olaparib.Approved, Investigational
SuvorexantThe serum concentration of Suvorexant can be increased when it is combined with Olaparib.Approved
Synthetic Conjugated Estrogens, AThe metabolism of Synthetic Conjugated Estrogens, A can be decreased when combined with Olaparib.Approved
Synthetic Conjugated Estrogens, BThe metabolism of Synthetic Conjugated Estrogens, B can be decreased when combined with Olaparib.Approved
TacrolimusThe metabolism of Tacrolimus can be decreased when combined with Olaparib.Approved, Investigational
TadalafilThe metabolism of Tadalafil can be decreased when combined with Olaparib.Approved, Investigational
TamoxifenThe metabolism of Tamoxifen can be decreased when combined with Olaparib.Approved
TamsulosinThe metabolism of Tamsulosin can be decreased when combined with Olaparib.Approved, Investigational
TasosartanThe metabolism of Tasosartan can be decreased when combined with Olaparib.Approved
Taurochenodeoxycholic acidThe metabolism of Taurochenodeoxycholic acid can be decreased when combined with Olaparib.Experimental
TelaprevirThe serum concentration of Olaparib can be increased when it is combined with Telaprevir.Approved
TelithromycinThe serum concentration of Olaparib can be increased when it is combined with Telithromycin.Approved
TemazepamThe metabolism of Temazepam can be decreased when combined with Olaparib.Approved
TemsirolimusThe metabolism of Temsirolimus can be decreased when combined with Olaparib.Approved
TeniposideThe metabolism of Teniposide can be decreased when combined with Olaparib.Approved
TerbinafineThe metabolism of Terbinafine can be decreased when combined with Olaparib.Approved, Investigational, Vet Approved
TerfenadineThe metabolism of Terfenadine can be decreased when combined with Olaparib.Withdrawn
TesmilifeneThe metabolism of Tesmilifene can be decreased when combined with Olaparib.Investigational
TestosteroneThe metabolism of Testosterone can be decreased when combined with Olaparib.Approved, Investigational
TetracyclineThe metabolism of Tetracycline can be decreased when combined with Olaparib.Approved, Vet Approved
TheophyllineThe metabolism of Theophylline can be decreased when combined with Olaparib.Approved
ThiotepaThe metabolism of Thiotepa can be decreased when combined with Olaparib.Approved
TiagabineThe metabolism of Tiagabine can be decreased when combined with Olaparib.Approved
TicagrelorThe metabolism of Ticagrelor can be decreased when combined with Olaparib.Approved
TiclopidineThe serum concentration of Olaparib can be increased when it is combined with Ticlopidine.Approved
TinidazoleThe metabolism of Tinidazole can be decreased when combined with Olaparib.Approved, Investigational
TiotropiumThe metabolism of Tiotropium can be decreased when combined with Olaparib.Approved
TipranavirThe metabolism of Tipranavir can be decreased when combined with Olaparib.Approved, Investigational
TocilizumabThe serum concentration of Olaparib can be decreased when it is combined with Tocilizumab.Approved
TofacitinibThe metabolism of Tofacitinib can be decreased when combined with Olaparib.Approved, Investigational
TolterodineThe metabolism of Tolterodine can be decreased when combined with Olaparib.Approved, Investigational
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Olaparib.Approved
ToremifeneThe metabolism of Toremifene can be decreased when combined with Olaparib.Approved, Investigational
TrabectedinThe serum concentration of Trabectedin can be increased when it is combined with Olaparib.Approved, Investigational
TramadolThe metabolism of Tramadol can be decreased when combined with Olaparib.Approved, Investigational
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Olaparib.Approved, Investigational
Trastuzumab emtansineThe metabolism of Trastuzumab emtansine can be decreased when combined with Olaparib.Approved
TrazodoneThe metabolism of Trazodone can be decreased when combined with Olaparib.Approved, Investigational
TretinoinThe metabolism of Tretinoin can be decreased when combined with Olaparib.Approved, Investigational, Nutraceutical
TriamcinoloneThe metabolism of Triamcinolone can be decreased when combined with Olaparib.Approved, Vet Approved
TriazolamThe metabolism of Triazolam can be decreased when combined with Olaparib.Approved
TrimethadioneThe metabolism of Trimethadione can be decreased when combined with Olaparib.Approved
TrimethoprimThe metabolism of Trimethoprim can be decreased when combined with Olaparib.Approved, Vet Approved
TrimipramineThe metabolism of Trimipramine can be decreased when combined with Olaparib.Approved
TroglitazoneThe metabolism of Troglitazone can be decreased when combined with Olaparib.Withdrawn
TroleandomycinThe metabolism of Troleandomycin can be decreased when combined with Olaparib.Approved
UdenafilThe metabolism of Udenafil can be decreased when combined with Olaparib.Approved, Investigational
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Olaparib.Approved
ValdecoxibThe metabolism of Valdecoxib can be decreased when combined with Olaparib.Investigational, Withdrawn
VandetanibThe metabolism of Vandetanib can be decreased when combined with Olaparib.Approved
VanoxerineThe metabolism of Vanoxerine can be decreased when combined with Olaparib.Investigational
VardenafilThe metabolism of Vardenafil can be decreased when combined with Olaparib.Approved
VemurafenibThe metabolism of Vemurafenib can be decreased when combined with Olaparib.Approved
VenetoclaxThe metabolism of Venetoclax can be decreased when combined with Olaparib.Approved
VenlafaxineThe serum concentration of Olaparib can be increased when it is combined with Venlafaxine.Approved
VerapamilThe serum concentration of Olaparib can be increased when it is combined with Verapamil.Approved
VicrivirocThe metabolism of Vicriviroc can be decreased when combined with Olaparib.Investigational
VilanterolThe metabolism of Vilanterol can be decreased when combined with Olaparib.Approved
VilazodoneThe serum concentration of Vilazodone can be increased when it is combined with Olaparib.Approved
VinblastineThe metabolism of Vinblastine can be decreased when combined with Olaparib.Approved
VincristineThe metabolism of Vincristine can be decreased when combined with Olaparib.Approved, Investigational
VindesineThe serum concentration of Vindesine can be increased when it is combined with Olaparib.Approved
VinorelbineThe metabolism of Vinorelbine can be decreased when combined with Olaparib.Approved, Investigational
VismodegibThe metabolism of Vismodegib can be decreased when combined with Olaparib.Approved
VoriconazoleThe serum concentration of Olaparib can be increased when it is combined with Voriconazole.Approved, Investigational
VortioxetineThe metabolism of Vortioxetine can be decreased when combined with Olaparib.Approved
WarfarinThe metabolism of Warfarin can be decreased when combined with Olaparib.Approved
YohimbineThe metabolism of Yohimbine can be decreased when combined with Olaparib.Approved, Vet Approved
ZafirlukastThe metabolism of Zafirlukast can be decreased when combined with Olaparib.Approved, Investigational
ZalcitabineThe metabolism of Zalcitabine can be decreased when combined with Olaparib.Approved
ZaleplonThe metabolism of Zaleplon can be decreased when combined with Olaparib.Approved, Illicit, Investigational
ZidovudineThe metabolism of Zidovudine can be decreased when combined with Olaparib.Approved
ZileutonThe metabolism of Zileuton can be decreased when combined with Olaparib.Approved, Investigational, Withdrawn
ZiprasidoneThe serum concentration of Olaparib can be increased when it is combined with Ziprasidone.Approved
ZolpidemThe metabolism of Zolpidem can be decreased when combined with Olaparib.Approved
ZomepiracThe metabolism of Zomepirac can be decreased when combined with Olaparib.Withdrawn
ZonisamideThe metabolism of Zonisamide can be decreased when combined with Olaparib.Approved, Investigational
ZopicloneThe serum concentration of Zopiclone can be increased when it is combined with Olaparib.Approved
ZuclopenthixolThe serum concentration of Zuclopenthixol can be increased when it is combined with Olaparib.Approved, Investigational
Food InteractionsNot Available
References
Synthesis Reference
  1. Menear KA, Adcock C, Boulter R, Cockcroft XL, Copsey L, Cranston A, Dillon KJ, Drzewiecki J, Garman S, Gomez S, Javaid H, Kerrigan F, Knights C, Lau A, Loh VM Jr, Matthews IT, Moore S, O’Connor MJ, Smith GC, Martin NM: 4-[3-(4-cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin- 1-one: a novel bioavailable inhibitor of poly(ADP-ribose) polymerase-1. J Med Chem. 2008 Oct 23;51(20):6581-91. doi: 10.1021/jm8001263. Epub 2008 Sep 19. Pubmed
General References
  1. Frampton JE: Olaparib: a review of its use as maintenance therapy in patients with ovarian cancer. BioDrugs. 2015 Apr;29(2):143-50. doi: 10.1007/s40259-015-0125-6. [PubMed:25899311 ]
  2. Menear KA, Adcock C, Boulter R, Cockcroft XL, Copsey L, Cranston A, Dillon KJ, Drzewiecki J, Garman S, Gomez S, Javaid H, Kerrigan F, Knights C, Lau A, Loh VM Jr, Matthews IT, Moore S, O'Connor MJ, Smith GC, Martin NM: 4-[3-(4-cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin- 1-one: a novel bioavailable inhibitor of poly(ADP-ribose) polymerase-1. J Med Chem. 2008 Oct 23;51(20):6581-91. doi: 10.1021/jm8001263. Epub 2008 Sep 19. [PubMed:18800822 ]
  3. Hay T, Matthews JR, Pietzka L, Lau A, Cranston A, Nygren AO, Douglas-Jones A, Smith GC, Martin NM, O'Connor M, Clarke AR: Poly(ADP-ribose) polymerase-1 inhibitor treatment regresses autochthonous Brca2/p53-mutant mammary tumors in vivo and delays tumor relapse in combination with carboplatin. Cancer Res. 2009 May 1;69(9):3850-5. doi: 10.1158/0008-5472.CAN-08-2388. Epub 2009 Apr 21. [PubMed:19383921 ]
  4. Rottenberg S, Jaspers JE, Kersbergen A, van der Burg E, Nygren AO, Zander SA, Derksen PW, de Bruin M, Zevenhoven J, Lau A, Boulter R, Cranston A, O'Connor MJ, Martin NM, Borst P, Jonkers J: High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs. Proc Natl Acad Sci U S A. 2008 Nov 4;105(44):17079-84. doi: 10.1073/pnas.0806092105. Epub 2008 Oct 29. [PubMed:18971340 ]
External Links
ATC CodesL01XX46
AHFS Codes
  • 10:00
PDB EntriesNot Available
FDA labelDownload (297 KB)
MSDSNot Available
ADMET
Predicted ADMET featuresNot Available
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage forms
FormRouteStrength
CapsuleOral50 mg
CapsuleOral50 mg/1
PricesNot Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US7151102 No2002-04-292022-04-29Us
US7449464 No2004-10-112024-10-11Us
US7981889 No2004-10-112024-10-11Us
US8143241 No2007-08-122027-08-12Us
US8247416 No2008-09-242028-09-24Us
US8859562 No2011-08-042031-08-04Us
US8912187 No2004-03-122024-03-12Us
Properties
StateSolid
Experimental PropertiesNot Available
Predicted Properties
PropertyValueSource
Water Solubility0.119 mg/mLALOGPS
logP2.68ALOGPS
logP2.32ChemAxon
logS-3.6ALOGPS
pKa (Strongest Acidic)8.75ChemAxon
pKa (Strongest Basic)2.21ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area86.63 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity118.63 m3·mol-1ChemAxon
Polarizability44.03 Å3ChemAxon
Number of Rings5ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as phthalazinones. These are compounds containing a phthalazine bearing a ketone group.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassNaphthyridines
Sub ClassPhthalazines
Direct ParentPhthalazinones
Alternative Parents
Substituents
  • Phthalazinone
  • Halobenzoic acid or derivatives
  • 2-halobenzoic acid or derivatives
  • Benzoic acid or derivatives
  • Benzamide
  • Benzoyl
  • Pyridazinone
  • Halobenzene
  • Fluorobenzene
  • Benzenoid
  • Pyridazine
  • Piperazine
  • 1,4-diazinane
  • Cyclopropanecarboxylic acid or derivatives
  • Monocyclic benzene moiety
  • Aryl halide
  • Aryl fluoride
  • Heteroaromatic compound
  • Vinylogous halide
  • Tertiary carboxylic acid amide
  • Tertiary amine
  • Lactam
  • Carboxamide group
  • Azacycle
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Organofluoride
  • Organohalogen compound
  • Carbonyl group
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External DescriptorsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Zinc ion binding
Specific Function:
Involved in the base excision repair (BER) pathway, by catalyzing the poly(ADP-ribosyl)ation of a limited number of acceptor proteins involved in chromatin architecture and in DNA metabolism. This modification follows DNA damages and appears as an obligatory step in a detection/signaling pathway leading to the reparation of DNA strand breaks. Mediates the poly(ADP-ribosyl)ation of APLF and CHFR...
Gene Name:
PARP1
Uniprot ID:
P09874
Molecular Weight:
113082.945 Da
References
  1. Verhagen CV, de Haan R, Hageman F, Oostendorp TP, Carli AL, O'Connor MJ, Jonkers J, Verheij M, van den Brekel MW, Vens C: Extent of radiosensitization by the PARP inhibitor olaparib depends on its dose, the radiation dose and the integrity of the homologous recombination pathway of tumor cells. Radiother Oncol. 2015 Sep;116(3):358-65. doi: 10.1016/j.radonc.2015.03.028. Epub 2015 May 13. [PubMed:25981132 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
Inhibitor
General Function:
Nad+ adp-ribosyltransferase activity
Specific Function:
Involved in the base excision repair (BER) pathway, by catalyzing the poly(ADP-ribosyl)ation of a limited number of acceptor proteins involved in chromatin architecture and in DNA metabolism. This modification follows DNA damages and appears as an obligatory step in a detection/signaling pathway leading to the reparation of DNA strand breaks.
Gene Name:
PARP2
Uniprot ID:
Q9UGN5
Molecular Weight:
66205.31 Da
References
  1. Verhagen CV, de Haan R, Hageman F, Oostendorp TP, Carli AL, O'Connor MJ, Jonkers J, Verheij M, van den Brekel MW, Vens C: Extent of radiosensitization by the PARP inhibitor olaparib depends on its dose, the radiation dose and the integrity of the homologous recombination pathway of tumor cells. Radiother Oncol. 2015 Sep;116(3):358-65. doi: 10.1016/j.radonc.2015.03.028. Epub 2015 May 13. [PubMed:25981132 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
Inhibitor
General Function:
Nad+ adp-ribosyltransferase activity
Specific Function:
Involved in the base excision repair (BER) pathway, by catalyzing the poly(ADP-ribosyl)ation of a limited number of acceptor proteins involved in chromatin architecture and in DNA metabolism. This modification follows DNA damages and appears as an obligatory step in a detection/signaling pathway leading to the reparation of DNA strand breaks. May link the DNA damage surveillance network to the ...
Gene Name:
PARP3
Uniprot ID:
Q9Y6F1
Molecular Weight:
60069.7 Da
References
  1. Verhagen CV, de Haan R, Hageman F, Oostendorp TP, Carli AL, O'Connor MJ, Jonkers J, Verheij M, van den Brekel MW, Vens C: Extent of radiosensitization by the PARP inhibitor olaparib depends on its dose, the radiation dose and the integrity of the homologous recombination pathway of tumor cells. Radiother Oncol. 2015 Sep;116(3):358-65. doi: 10.1016/j.radonc.2015.03.028. Epub 2015 May 13. [PubMed:25981132 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Verhagen CV, de Haan R, Hageman F, Oostendorp TP, Carli AL, O'Connor MJ, Jonkers J, Verheij M, van den Brekel MW, Vens C: Extent of radiosensitization by the PARP inhibitor olaparib depends on its dose, the radiation dose and the integrity of the homologous recombination pathway of tumor cells. Radiother Oncol. 2015 Sep;116(3):358-65. doi: 10.1016/j.radonc.2015.03.028. Epub 2015 May 13. [PubMed:25981132 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inducer
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Acts as a 1,4-cineole 2-exo-monooxygenase.
Gene Name:
CYP2B6
Uniprot ID:
P20813
Molecular Weight:
56277.81 Da
References
  1. Verhagen CV, de Haan R, Hageman F, Oostendorp TP, Carli AL, O'Connor MJ, Jonkers J, Verheij M, van den Brekel MW, Vens C: Extent of radiosensitization by the PARP inhibitor olaparib depends on its dose, the radiation dose and the integrity of the homologous recombination pathway of tumor cells. Radiother Oncol. 2015 Sep;116(3):358-65. doi: 10.1016/j.radonc.2015.03.028. Epub 2015 May 13. [PubMed:25981132 ]
Comments
comments powered by Disqus
Drug created on May 14, 2015 14:38 / Updated on December 04, 2016 02:45